North American Scientific to divest NOMOS

Twitter icon
Facebook icon
LinkedIn icon
e-mail icon
Google icon

North American Scientific (NAS) announced that it has decided to divest its NOMOS Radiation Oncology business. The Chatsworth, Calif.-based firm said it is working with a financial advisor to formalize the final details of the divesture of the business.

NAS said it will focus on the marketing and development of brachytherapy products for the treatment of cancer, including its Prospera brachytherapy seeds and SurTrak needles and strands used primarily in the treatment of prostate cancer. It also reported that it is on track to commercialize its ClearPath multi-channel catheter breast-brachytherapy devices this year.